All In Biotech

Drug Trial Radar · NCT06369935

A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.

Last checked: Nov 20, 2026Latest source record: Apr 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

260

Planned (sponsor's estimate)

Start

Jun 20, 2024

Primary completion

Aug 20, 2026

Study completion Aug 20, 2027

Sponsor

Lead sponsor
Peking University People's HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 17, 2024

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, observational, single-arm real world study. The purpose of this study is to describe demographic and disease characteristics, treatment patterns, and clinical outcomes in the real-world setting among participants in China with relapsed/refractory multiple myeloma (RRMM) who have been treated with Equecabtagene Autoleucel. This study will use both prospective and retrospective data

Conditions

  • Relapsed/Refractory Multiple Myeloma

Interventions

  • Equecabtagene AutoleucelDrug

    Equecabtagene Autoleucel (CT103A) is a novel fully human BCMA-targeting CAR-T therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Best Overall Response Rate, BORTime frame: up to 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.